Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

Healthcare Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

Bullboard (TSX:CSCI)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Post by lscfaon Aug 27, 2024 2:16pm

Down 54% from merger anouncement date

$8.72 US => $3.98 US.   Gagnon must go.
47
Discussion
Post by fossi_2002on Aug 27, 2024 12:57pm

Adult trial failed to meet primary endpoint but was approved

Proph... this is a message board for shareholders and not for “would-be analysts”. Those who invest their capital in the stock market want it to earn interest and want the board to be good stewards of ...more  
86
Discussion
Comment by prophetoffactzon Aug 27, 2024 12:27pm

RE:Adult trial failed to meet primary endpoint but was approved

fossi, why not provide your analysis for how the other tests concluded the patients were growth hormone deficient yet macimorelin showed the same patients could produce growth hormone? This is a very ...more  
55
Discussion
Post by fossi_2002on Aug 27, 2024 11:50am

Adult trial failed to meet primary endpoint but was approved

Proph... is grasping at the last straw. Everything is useless. Further losses loom and the listing on the NASDAQ is a distant prospect. In order for Gilles to achieve his goal, he will consider ...more  
95
Discussion
Post by prophetoffactzon Aug 27, 2024 11:30am

Adult trial failed to meet primary endpoint but was approved

For the adult trial: In January 2017, Aeterna Zentaris announced that the confirmatory Phase 3 clinical trial of Macrilen (macimorelin) for diagnosing adult growth hormone deficiency (AGHD) failed to ...more  
81
Post by jrsloan60on Aug 27, 2024 10:54am

Well I guess we made it to the NASDAQ

Trades no shares and keeps falling like a there's no bottom. This reminds me of Trinidad drilling when they started to build a big shop so they could build massive amounts of rigs. Just blowing ...more  
89
Comment by prophetoffactzon Aug 27, 2024 10:18am

RE:RE:New Press Release - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

It was suppose to show macimorelin's reproducability at two meaningfully different time points. Putting time between the two macimorelin tests would have helped prove macimorelin could produce the ...more  
65
Discussion
Comment by lscfaon Aug 27, 2024 10:05am

RE:New Press Release - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Who's the bonehead designing these studies?  Why not do the 2 Macimorelin tests first, followed by the comparator tests?  Why the hell do comparator tests in between Macimorelin tests?
53
Discussion
Post by prophetoffactzon Aug 27, 2024 9:53am

If the industry is falsely over-diagnosing children

with growth hormone deficiency with those other tests does it have a problem?
48
Post by fossi_2002on Aug 27, 2024 9:51am

Perplexity Ai:

Proph... tries to predict a victory from a defeat. Proph... tries to predict a win from a huge loss. Proph... tries to turn an absolute loser like Gilles into a winner. - what else do you want to tell ...more  
76
Post by prophetoffactzon Aug 27, 2024 9:31am

Perplexity Ai:

Based on the information provided, there is a strong case for the FDA to consider accepting a higher cut-off point for the macimorelin test in diagnosing growth hormone deficiency (GHD), particularly ...more  
58
Post by prophetoffactzon Aug 27, 2024 9:05am

Perplexity Ai

Based on the unexpected results from the DETECT trial, there are a few potential reasons why children who were thought to be growth hormone deficient based on other tests produced growth hormone in ...more  
61
Post by prophetoffactzon Aug 27, 2024 8:57am

Perplexity Ai:

Based on the press release, it appears that the Phase 3 DETECT trial of macimorelin for diagnosing childhood-onset growth hormone deficiency (CGHD) did not meet its primary efficacy endpoint as ...more  
59
Comment by prophetoffactzon Aug 27, 2024 8:50am

RE:RE:The unexpected

Macimorelin is a key asset and could finance the path forward. Is it the asset the US knows most about and the response of the market to this news may therefore overweight its significance? What is ...more  
48
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities